Estimation of the Restricted Mean Duration of Response (RMDoR) in Oncology.

IF 1.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Antonios Daletzakis, Kit C B Roes, Marianne A Jonker
{"title":"Estimation of the Restricted Mean Duration of Response (RMDoR) in Oncology.","authors":"Antonios Daletzakis, Kit C B Roes, Marianne A Jonker","doi":"10.1002/pst.2468","DOIUrl":null,"url":null,"abstract":"<p><p>The duration of response (DoR) is defined as the time from the onset of response to treatment up to progression of disease or death due to any reason, whichever occurs earlier. The expected DoR could be a suitable estimand to measure the efficacy of a treatment but is in practice difficult to estimate, since patients' follow-up times are often right-censored. Instead, the restricted mean duration of response (RMDoR) is often used. The RMDoR in a time <math> <semantics><mrow><mi>τ</mi></mrow> <annotation>$$ \\tau $$</annotation></semantics> </math> is equal to the expected DoR restricted to the interval <math> <semantics> <mrow><mfenced><mn>0</mn> <mi>τ</mi></mfenced> </mrow> <annotation>$$ \\left[0,\\tau \\right] $$</annotation></semantics> </math> . In this paper, we consider the behaviour of the RMDoR as a function of <math> <semantics><mrow><mi>τ</mi></mrow> <annotation>$$ \\tau $$</annotation></semantics> </math> and its suitability as a measure to quantify the efficacy of a treatment. Besides, we focus on the estimation of the RMDoR. In oncology, the events response to treatment and progression of disease are typically detected through time-scheduled scans and are therefore interval-censored. We describe multiple estimators for the RMDoR that deal with the interval censoring in different ways and study the performance of these estimators in single arm trials and randomised controlled trials.</p>","PeriodicalId":19934,"journal":{"name":"Pharmaceutical Statistics","volume":"24 1","pages":"e2468"},"PeriodicalIF":1.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11803436/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pst.2468","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The duration of response (DoR) is defined as the time from the onset of response to treatment up to progression of disease or death due to any reason, whichever occurs earlier. The expected DoR could be a suitable estimand to measure the efficacy of a treatment but is in practice difficult to estimate, since patients' follow-up times are often right-censored. Instead, the restricted mean duration of response (RMDoR) is often used. The RMDoR in a time τ $$ \tau $$ is equal to the expected DoR restricted to the interval 0 τ $$ \left[0,\tau \right] $$ . In this paper, we consider the behaviour of the RMDoR as a function of τ $$ \tau $$ and its suitability as a measure to quantify the efficacy of a treatment. Besides, we focus on the estimation of the RMDoR. In oncology, the events response to treatment and progression of disease are typically detected through time-scheduled scans and are therefore interval-censored. We describe multiple estimators for the RMDoR that deal with the interval censoring in different ways and study the performance of these estimators in single arm trials and randomised controlled trials.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmaceutical Statistics
Pharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.70
自引率
6.70%
发文量
90
审稿时长
6-12 weeks
期刊介绍: Pharmaceutical Statistics is an industry-led initiative, tackling real problems in statistical applications. The Journal publishes papers that share experiences in the practical application of statistics within the pharmaceutical industry. It covers all aspects of pharmaceutical statistical applications from discovery, through pre-clinical development, clinical development, post-marketing surveillance, consumer health, production, epidemiology, and health economics. The Journal is both international and multidisciplinary. It includes high quality practical papers, case studies and review papers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信